Role of MAST3 kinase in developmental and epileptic encephalopathy
Role of MAST3 kinase in developmental and epileptic encephalopathy
批准号:
10217382
负责人:
ANGUS C. NAIRN
金额:
$14.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-15 至 2023-04-14
关键词:
AcidsAddressAffectAffinity ChromatographyAntibodiesAreaBiochemicalBiologicalBiological AssayBrainCell physiologyCellsCerebral PalsyCerebral cortexChildChildhoodCongenital cerebellar hypoplasiaCorpus CallosumCorpus striatum structureCortical MalformationCountryDataDevelopmentDevelopmental Delay DisordersDevelopmental Therapeutics ProgramDiagnosisDiagnosticDiseaseElectrophysiology (science)EpilepsyFamilyGenesGenetic DiseasesGenetic ResearchGoalsHippocampus (Brain)In VitroIncomeIndividualInfectionInjuryIntellectual functioning disabilityInterventionLeadLentivirus VectorLifeLinkMass Spectrum AnalysisMicrotubulesMissense MutationModelingMolecularMorphologyMutationNeuraxisNeurologicNeuronsPathogenesisPatientsPharmaceutical PreparationsPhenotypePhosphorylationPhosphotransferasesPhysiologicalPlayPrevalencePromegaPropertyProtein Phosphatase 2A Regulatory Subunit PR53Protein Serine/Threonine PhosphataseProtein phosphataseProtein-Serine-Threonine KinasesProteinsQuality of lifeRecombinant ProteinsRecombinantsResearchRett SyndromeRiskRoleSignal TransductionSyndromeTechniquesTestingUnited StatesVariantVertebral columnchildhood epilepsycyclic AMP-regulated phosphoprotein 16epileptic encephalopathiesexperimental studygain of functionhealth care qualityimprovedinhibitor/antagonistknock-downloss of function mutationlow and middle-income countriesmental developmentmutantnervous system disorderneuron developmentnovel diagnosticsnovel therapeuticstargeted treatmenttool
中文摘要
癫痫是全球最常见的神经系统疾病之一,据估计,
美国和全球5000万人。令人担忧的是,即使在高收入国家,癫痫病也在一个-
三分之一的患者抵制常规药物干预,突出表明需要进一步了解
发病机制和与这种疾病相关的分子变化。发育性和癫痫性
脑病(DEE)是癫痫研究中一个相对较新的概念,
基因的变异,如突变,会导致癫痫样活动增加和精神活动减慢。
发展最近,一些发育神经系统疾病,如Rett综合征,脑瘫,
以及伴有小脑发育不全和皮质畸形的巨大胼胝体综合征,
与微管相关丝氨酸/苏氨酸(MAST)蛋白激酶家族中的突变相关。
具体来说,我们的同事已经发现了7名DEE患者,他们在基因组中存在新生错义突变。
MAST 3基因:G510 S、G515 S、L516 P和V551 L。我们的研究小组最近在大脑中发现,MAST 3
使ARPP-16磷酸化,ARPP-16是一种在纹状体和皮质中富集的小的热和酸稳定蛋白,在Ser 46,
转化为丝氨酸/苏氨酸磷酸酶PP 2A的有效抑制剂。初步结果表明,
MAST 3中的DEE突变导致MAST 3活性的功能获得性增加,促进ARPP-16
在Ser 46磷酸化,这将导致随后抑制特定形式的PP 2A。有趣的是,
其他最近的研究已经确定了催化C和底物靶向B的功能突变的丧失
亚基,PP 2A在智力残疾和发育迟缓的人,其中大多数也
患有癫痫。我们假设MAST 3活性的增加和PP 2A信号的选择性干扰,
可能在儿童神经系统疾病的发展中起部分致病作用。拟议
研究包含两个具体目的,以检验DEE MAST 3突变增加激酶活性的假设。
活性,并可能改变其相互作用体,导致神经元发育的有害变化。目标1将
确定哪些蛋白质和底物与MAST 3相互作用,当DEE
MAST 3突变被引入,以及这如何影响激酶活性。这一目标将通过体外
生物化学技术,例如用重组蛋白的激酶测定,以及在原代细胞中的pulldown测定。
神经元培养以鉴定相互作用的蛋白质和底物。目标2将研究DEE的作用
使用原代神经元培养物可视化树突状细胞的神经元发育和功能中的MAST 3突变
树枝化和刺,形态学变化和电生理特性。由此获得的结果
这项研究将进一步阐明MAST 3成为几种发展中的重要力量的潜力。
早期的神经系统疾病了解这一机制将导致新的诊断工具,
旨在改善受这些疾病影响的个人的生活质量的干预措施。
英文摘要
Epilepsy is one of the most common neurological disorders globally, estimated to affect 3.4 million people in
the United States and 50 million people globally. Alarmingly, even in high-income countries, epilepsy in one-
third of patients resists conventional drug intervention, highlighting the need to further understand the
pathogenesis and molecular changes associated with this disease. Developmental and epileptic
encephalopathy (DEE) is a relatively new concept in epilepsy research that describes genetic disorders in
which a variation in a gene, such as a mutation, causes increased epileptiform activity and slowing of mental
development. Recently, several developmental neurological conditions, such as Rett syndrome, cerebral palsy,
and mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations have been
associated with mutations in the microtubule-associated serine/threonine (MAST) protein kinase family.
Specifically, our colleagues have discovered seven individuals with DEE with de novo missense mutations in
the MAST3 gene: G510S, G515S, L516P, and V551L. Our group recently showed in brain that MAST3
phosphorylates ARPP-16, a small heat- and acid-stable protein enriched in striatum and cortex, at Ser46,
converting it into a potent inhibitor of the serine/threonine phosphatase PP2A. Preliminary results suggest the
DEE mutations in MAST3 cause a gain-of-function increase in MAST3 activity, promoting ARPP-16
phosphorylation at Ser46 which would lead to subsequent inhibition of specific forms of PP2A. Interestingly,
other recent studies have identified loss of function mutations in the catalytic C, and substrate targeting B
subunits, of PP2A in individuals with intellectual disability and developmental delay, the majority of which also
have epilepsy. We hypothesize that increased MAST3 activity, and selective perturbation of PP2A signaling,
may in part play a causative role in the development of childhood neurological conditions. The proposed
research contains two specific aims to test the hypothesis that the DEE MAST3 mutations increase kinase
activity and may change its interactome, causing detrimental changes in neuronal development. Aim 1 will
determine which proteins and substrates interact with MAST3, how this interactome changes when the DEE
MAST3 mutations are introduced, and how this affects kinase activity. This aim will be achieved using in vitro
biochemical techniques, such as kinase assays with recombinant proteins, and pulldown assays in primary
neuron cultures to identify interacting proteins and substrates. Aim 2 will investigate the role of the DEE
MAST3 mutations in neuronal development and function using primary neuron cultures to visualize dendritic
arborization and spines, morphological changes, and electrophysiological properties. Results gained from this
study will further elucidate the potential for MAST3 to be a prominent force in the development of several
neurological conditions early in life. Understanding this mechanism should lead to new diagnostic tools and
interventions aimed at improving the quality of life of individuals affected by these disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarker Core
-
批准号:10431898
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2020
-
负责人:ANGUS C. NAIRN
-
依托单位:
Biomarker Core
-
批准号:9921658
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2020
-
负责人:ANGUS C. NAIRN
-
依托单位:
Biomarker Core
-
批准号:10180855
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2020
-
负责人:ANGUS C. NAIRN
-
依托单位:
Biomarker Core
-
批准号:10620824
-
项目类别:
-
资助金额:$41.87万
-
财政年份:2020
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:8361496
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2011
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:8169111
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2010
-
负责人:ANGUS C. NAIRN
-
依托单位:
Biochemical Mechanisms Mediating Cell Type-Specific Actions of Antipsychotic Drug
-
批准号:8150123
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2010
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:7954065
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2009
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:7722200
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2008
-
负责人:ANGUS C. NAIRN
-
依托单位:
Striatal Phosphoproteins and the Actions of the Psychostimulants
-
批准号:7513633
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2007
-
负责人:ANGUS C. NAIRN
-
依托单位:
ID OF IN VITRO PHOSPHORYLATION SITES WITHIN ELONGATION FACTOR 2 KINASE
-
批准号:7355047
-
项目类别:
-
资助金额:$0.25万
-
财政年份:2006
-
负责人:ANGUS C. NAIRN
-
依托单位:
STRIATAL PHOSPHOPROTEINS AND THE ACTIONS OF PSYCHOSTIMULANTS
-
批准号:7057578
-
项目类别:
-
资助金额:$25.64万
-
财政年份:2006
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:7355066
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2006
-
负责人:ANGUS C. NAIRN
-
依托单位:
IN VITRO AUTOPHOSPHORYLATION SITES WITHIN CHAK,CALCIUM CHANNEL
-
批准号:7355032
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2006
-
负责人:ANGUS C. NAIRN
-
依托单位:
IN VITRO AUTOPHOSPHORYLATION SITES WITHIN CHAK,CALCIUM CHANNEL
-
批准号:7179916
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2005
-
负责人:ANGUS C. NAIRN
-
依托单位:
ID OF IN VITRO PHOSPHORYLATION SITES WITHIN ELONGATION FACTOR 2 KINASE
-
批准号:7179932
-
项目类别:
-
资助金额:$0.24万
-
财政年份:2005
-
负责人:ANGUS C. NAIRN
-
依托单位:
CDK5/P35 PHOSPHORYLATION
-
批准号:7179962
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2005
-
负责人:ANGUS C. NAIRN
-
依托单位:
Bioinformatics and Biostatistics Core
-
批准号:10408094
-
项目类别:
-
资助金额:$33.12万
-
财政年份:2004
-
负责人:ANGUS C. NAIRN
-
依托单位:
Yale/NIDA Neuroproteomics Center
-
批准号:10025465
-
项目类别:
-
资助金额:$161.61万
-
财政年份:2004
-
负责人:ANGUS C. NAIRN
-
依托单位:
Yale/NIDA Neuroproteomics Center
-
批准号:10646378
-
项目类别:
-
资助金额:$161.61万
-
财政年份:2004
-
负责人:ANGUS C. NAIRN
-
依托单位:
海外基金